Agency Information Collection Activities: Submission for OMB Review; Comment Request, 53107-53109 [2024-13891]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 122 / Tuesday, June 25, 2024 / Notices
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–13868 Filed 6–24–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifiers: CMS–10280]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995
(PRA), federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information (including each proposed
extension or reinstatement of an existing
collection of information) and to allow
60 days for public comment on the
proposed action. Interested persons are
invited to send comments regarding our
burden estimates or any other aspect of
this collection of information, including
the necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions,
the accuracy of the estimated burden,
ways to enhance the quality, utility, and
clarity of the information to be
collected, and the use of automated
collection techniques or other forms of
information technology to minimize the
information collection burden.
DATES: Comments must be received by
August 26, 2024.
ADDRESSES: When commenting, please
reference the document identifier or
OMB control number. To be assured
consideration, comments and
recommendations must be submitted in
any one of the following ways:
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:03 Jun 24, 2024
Jkt 262001
1. Electronically. You may send your
comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) that are accepting
comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number:l, Room C4–26–05,
7500 Security Boulevard, Baltimore,
Maryland 21244–1850.
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, please access the CMS PRA
website by copying and pasting the
following web address into your web
browser: https://www.cms.gov/
Regulations-and-Guidance/Legislation/
PaperworkReductionActof1995/PRAListing.
FOR FURTHER INFORMATION CONTACT:
William N. Parham at (410) 786–4669.
SUPPLEMENTARY INFORMATION:
Contents
This notice sets out a summary of the
use and burden associated with the
following information collections. More
detailed information can be found in
each collection’s supporting statement
and associated materials (see
ADDRESSES).
CMS–10280 Home Health Change of
Care Notice
Under the PRA (44 U.S.C. 3501–
3520), federal agencies must obtain
approval from the Office of Management
and Budget (OMB) for each collection of
information they conduct or sponsor.
The term ‘‘collection of information’’ is
defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA
requires federal agencies to publish a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension or reinstatement of an existing
collection of information, before
submitting the collection to OMB for
approval. To comply with this
requirement, CMS is publishing this
notice.
Information Collection
1. Type of Information Collection
Request: Extension of a currently
approved collection; Titles of
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
53107
Information Collection: Home Health
Change of Care Notice; Use: The
purpose of the Home Health Change of
Care Notice (HHCCN) is to notify
original Medicare beneficiaries
receiving home health care benefits of
plan of care changes. Consistent with
the Medicare Conditions of
Participation (COPs) for home health
agencies (HHAs) and the decision of the
US Court of Appeals 2nd Circuit
decision in Lutwin v. Thompson, HHAs
must provide the HHCCN to a
beneficiary whenever they reduce or
terminate that beneficiary’s home health
services due to physician/provider
orders or limitation of the HHA in
providing the specific service.
Notification is required for covered and
non-covered services listed in the plan
of care (POC). Implementing regulations
are found at 42 CFR 484.10(c). These
requirements are fulfilled by the
HHCCN.
Home health agencies (HHAs) are
required to provide written notice to
Original Medicare beneficiaries under
various circumstances involving the
reduction or termination of items and/
or services consistent with Home Health
Agencies Conditions of Participation
(COPs). The beneficiary will use the
information provided to decide whether
or not to pursue alternative options to
continue receiving the care noted on the
HHCCN. Form Numbers: CMS–10280
(OMB control number: 0938–1196);
Frequency: Yearly; Affected Public:
Private Sector—Business or other forprofit and Not-for-profit institutions;
Number of Respondents: 11,353; Total
Annual Responses: 19,004,850; Total
Annual Hours: 1,265,723. (For policy
questions regarding this collection
contact, Jennifer Mccormick at 410–
786–2852.)
William N. Parham, III,
Director, Division of Information Collections
and Regulatory Impacts, Office of Strategic
Operations and Regulatory Affairs.
[FR Doc. 2024–13892 Filed 6–24–24; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifiers: CMS–1694 and CMS–
R–246]
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
AGENCY:
E:\FR\FM\25JNN1.SGM
25JNN1
53108
ACTION:
Federal Register / Vol. 89, No. 122 / Tuesday, June 25, 2024 / Notices
Notice.
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995
(PRA), federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension or reinstatement of an existing
collection of information, and to allow
a second opportunity for public
comment on the notice. Interested
persons are invited to send comments
regarding the burden estimate or any
other aspect of this collection of
information, including the necessity and
utility of the proposed information
collection for the proper performance of
the agency’s functions, the accuracy of
the estimated burden, ways to enhance
the quality, utility, and clarity of the
information to be collected, and the use
of automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
DATES: Comments on the collection(s) of
information must be received by the
OMB desk officer by July 25, 2024.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, please access the CMS PRA
website by copying and pasting the
following web address into your web
browser: https://www.cms.gov/
Regulations-and-Guidance/Legislation/
PaperworkReductionActof1995/PRAListing.
FOR FURTHER INFORMATION CONTACT:
William Parham at (410) 786–4669.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. The term ‘‘collection of
information’’ is defined in 44 U.S.C.
3502(3) and 5 CFR 1320.3(c) and
includes agency requests or
requirements that members of the public
submit reports, keep records, or provide
information to a third party. Section
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:03 Jun 24, 2024
Jkt 262001
3506(c)(2)(A) of the PRA (44 U.S.C.
3506(c)(2)(A)) requires federal agencies
to publish a 30-day notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension or
reinstatement of an existing collection
of information, before submitting the
collection to OMB for approval. To
comply with this requirement, CMS is
publishing this notice that summarizes
the following proposed collection(s) of
information for public comment:
1. Type of Information Collection
Request: Revision of a currently
approved collection; Title of
Information Collection: Appointment of
Representative and Supporting
Regulations in 42 CFR 405.910; Use:
The requirements for appointing
representatives for claims and appeals
processed under 42 CFR part 405
subpart I were codified into regulation
at 42 CFR 405.910. In summary, section
405.910 states an individual or entity
may appoint a representative to act on
their behalf in exercising their rights
relative to an initial claim determination
or an appeal. The appointment of
representation must be in writing and
must include all the required elements
specified in 405.910(c). The burden
associated with this requirement is the
time and effort of the individual or
entity to prepare an appointment of
representation containing all the
required information of this section. To
reduce some of the burden associated
with this requirement, we developed a
standardized form that the individual/
entity may opt (but is not required) to
use.
This form would be completed by
Medicare beneficiaries, providers and
suppliers (typically their billing clerk,
or billing company), and any party who
wish to appoint a representative to
assist them with their initial Medicare
claims determinations and filing
appeals on Medicare claims. The
information supplied on the form is
reviewed by Medicare claims and
appeals adjudicators. The adjudicators
make determinations whether the form
was completed accurately, and if the
form is correct and accepted, the form
is appended to the claim or appeal that
it was filed with. Form Number: CMS–
1696 (OMB control number: 0938–
0950); Frequency: Occasionally;
Affected Public: Individuals and
Households and Private Sector; Number
of Respondents: 213,208; Total Annual
Responses: 213,208; Total Annual
Hours: 53,302. (For policy questions
regarding this collection contact Liz
Hosna at 410–786–4993.
2. Type of Information Collection
Request: Revision of a currently
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
approved collection; Title of
Information Collection: Medicare
Advantage, Medicare Part D, and
Medicare Fee-For-Service Consumer
Assessment of Healthcare Providers and
Systems (CAHPS) Survey; Use: CMS is
required to collect and report
information on the quality of health care
services and prescription drug coverage
available to persons enrolled in a
Medicare health or prescription drug
plan under provisions in the Medicare
Prescription Drug, Improvement, and
Modernization Act of 2003 (MMA).
Specifically, the MMA under Sec.
1860D–4 (Information to Facilitate
Enrollment) requires CMS to conduct
consumer satisfaction surveys regarding
Medicare prescription drug plans and
Medicare Advantage plans and report
this information to Medicare
beneficiaries prior to the Medicare
annual enrollment period. The Medicare
CAHPS survey meets the requirement of
collecting and publicly reporting
consumer satisfaction information. The
Balanced Budget Act of 1997 also
requires the collection of information
about fee-for-service plans. The CAHPS
survey measures are incorporated into
the Part C and D Star Ratings that are
published on www.medicare.gov each
fall to help consumers choose a
Medicare plan. A subset of the CAHPS
measures is also included in the
Medicare & You Handbook. CAHPS
information from MA contracts also
feeds into the calculation of MA Quality
Bonus Payment Ratings that are
required by statute and regulation.
The primary purpose of the Medicare
CAHPS surveys is to provide
information to Medicare beneficiaries to
help them make more informed choices
among health and prescription drug
plans available to them. Survey results
are reported by CMS in the Medicare &
You Handbook published each fall and
on the Medicare Plan Finder website.
Beneficiaries can compare CAHPS
scores for each health and drug plan as
well as compare MA and FFS scores
when making enrollment decisions. The
Medicare CAHPS also provides data to
help CMS and others monitor the
quality and performance of Medicare
health and prescription drug plans and
identify areas to improve the quality of
care and services provided to enrollees
of these plans. CAHPS data are included
in the Medicare Part C & D Star Ratings
and used to calculate MA Quality Bonus
Payments. Form Number: CMS–R–246
(OMB control number: 0938–0732);
Frequency: Yearly; Affected Public:
Individuals and Households Number of
Respondents: 794,500; Total Annual
Responses: 794,500; Total Annual
E:\FR\FM\25JNN1.SGM
25JNN1
Federal Register / Vol. 89, No. 122 / Tuesday, June 25, 2024 / Notices
Hours: 192,265. (For policy questions
regarding this collection contact Lauren
Fuentes at 410–786–2290 or
lauren.fuentes@cms.hhs.gov).
William N. Parham, III,
Director, Division of Information Collections
and Regulatory Impacts, Office of Strategic
Operations and Regulatory Affairs.
[FR Doc. 2024–13891 Filed 6–24–24; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2023–N–2177]
Laboratory Developed Tests: Small
Entity Compliance Guide; Guidance for
Laboratory Manufacturers and Food
and Drug Administration Staff;
Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of availability.
The Food and Drug
Administration (FDA or Agency) is
announcing the availability of a final
guidance entitled ‘‘Laboratory
Developed Tests: Small Entity
Compliance Guide.’’ The laboratory
developed tests (LDT) final rule
amended FDA’s regulations to make
explicit that in vitro diagnostic products
(IVDs) are devices under the Federal
Food, Drug, and Cosmetic Act (FD&C
Act) including when the manufacturer
of the IVD is a laboratory. This small
entity compliance guide (SECG) is
intended to help small entities comply
with applicable medical device
regulations, consistent with the LDT
final rule, including the phasing out of
FDA’s general enforcement discretion
approach for LDTs so that IVDs
manufactured by a laboratory will
generally fall under the same
enforcement approach as other IVDs.
DATES: The announcement of the
guidance is published in the Federal
Register on June 25, 2024.
ADDRESSES: You may submit either
electronic or written comments on
Agency guidances at any time as
follows:
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
VerDate Sep<11>2014
17:03 Jun 24, 2024
Jkt 262001
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2023–N–2177 for ‘‘Laboratory
Developed Tests: Small Entity
Compliance Guide.’’ Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday
through Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
53109
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
You may submit comments on any
guidance at any time (see 21 CFR
10.115(g)(5)).
An electronic copy of the guidance
document is available for download
from the internet. See the
SUPPLEMENTARY INFORMATION section for
information on electronic access to the
guidance. Submit written requests for a
single hard copy of the guidance
document entitled ‘‘Laboratory
Developed Tests: Small Entity
Compliance Guide’’ to the Office of
Policy, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5431, Silver Spring,
MD 20993–0002. Send one selfaddressed adhesive label to assist that
office in processing your request.
FOR FURTHER INFORMATION CONTACT:
Brittany Schuck, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5422, Silver Spring,
MD 20993–0002, 301–796–5199,
LDTFinalRule@fda.hhs.gov; or James
Myers, Center for Biologics Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 71, Rm. 7301, Silver Spring,
MD 20993, 240–402–7911.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of May 6, 2024
(89 FR 37286), FDA issued a final rule
to amend its regulations to make
explicit that IVDs are devices under the
FD&C Act including when the
E:\FR\FM\25JNN1.SGM
25JNN1
]]>Agencies
[Federal Register Volume 89, Number 122 (Tuesday, June 25, 2024)]
[Notices]
[Pages 53107-53109]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-13891]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[Document Identifiers: CMS-1694 and CMS-R-246]
Agency Information Collection Activities: Submission for OMB
Review; Comment Request
AGENCY: Centers for Medicare & Medicaid Services, Health and Human
Services (HHS).
[[Page 53108]]
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Medicare & Medicaid Services (CMS) is
announcing an opportunity for the public to comment on CMS' intention
to collect information from the public. Under the Paperwork Reduction
Act of 1995 (PRA), federal agencies are required to publish notice in
the Federal Register concerning each proposed collection of
information, including each proposed extension or reinstatement of an
existing collection of information, and to allow a second opportunity
for public comment on the notice. Interested persons are invited to
send comments regarding the burden estimate or any other aspect of this
collection of information, including the necessity and utility of the
proposed information collection for the proper performance of the
agency's functions, the accuracy of the estimated burden, ways to
enhance the quality, utility, and clarity of the information to be
collected, and the use of automated collection techniques or other
forms of information technology to minimize the information collection
burden.
DATES: Comments on the collection(s) of information must be received by
the OMB desk officer by July 25, 2024.
ADDRESSES: Written comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function.
To obtain copies of a supporting statement and any related forms
for the proposed collection(s) summarized in this notice, please access
the CMS PRA website by copying and pasting the following web address
into your web browser: https://www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRA-Listing.
FOR FURTHER INFORMATION CONTACT: William Parham at (410) 786-4669.
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. The term ``collection of
information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and
includes agency requests or requirements that members of the public
submit reports, keep records, or provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires
federal agencies to publish a 30-day notice in the Federal Register
concerning each proposed collection of information, including each
proposed extension or reinstatement of an existing collection of
information, before submitting the collection to OMB for approval. To
comply with this requirement, CMS is publishing this notice that
summarizes the following proposed collection(s) of information for
public comment:
1. Type of Information Collection Request: Revision of a currently
approved collection; Title of Information Collection: Appointment of
Representative and Supporting Regulations in 42 CFR 405.910; Use: The
requirements for appointing representatives for claims and appeals
processed under 42 CFR part 405 subpart I were codified into regulation
at 42 CFR 405.910. In summary, section 405.910 states an individual or
entity may appoint a representative to act on their behalf in
exercising their rights relative to an initial claim determination or
an appeal. The appointment of representation must be in writing and
must include all the required elements specified in 405.910(c). The
burden associated with this requirement is the time and effort of the
individual or entity to prepare an appointment of representation
containing all the required information of this section. To reduce some
of the burden associated with this requirement, we developed a
standardized form that the individual/entity may opt (but is not
required) to use.
This form would be completed by Medicare beneficiaries, providers
and suppliers (typically their billing clerk, or billing company), and
any party who wish to appoint a representative to assist them with
their initial Medicare claims determinations and filing appeals on
Medicare claims. The information supplied on the form is reviewed by
Medicare claims and appeals adjudicators. The adjudicators make
determinations whether the form was completed accurately, and if the
form is correct and accepted, the form is appended to the claim or
appeal that it was filed with. Form Number: CMS-1696 (OMB control
number: 0938-0950); Frequency: Occasionally; Affected Public:
Individuals and Households and Private Sector; Number of Respondents:
213,208; Total Annual Responses: 213,208; Total Annual Hours: 53,302.
(For policy questions regarding this collection contact Liz Hosna at
410-786-4993.
2. Type of Information Collection Request: Revision of a currently
approved collection; Title of Information Collection: Medicare
Advantage, Medicare Part D, and Medicare Fee-For-Service Consumer
Assessment of Healthcare Providers and Systems (CAHPS) Survey; Use: CMS
is required to collect and report information on the quality of health
care services and prescription drug coverage available to persons
enrolled in a Medicare health or prescription drug plan under
provisions in the Medicare Prescription Drug, Improvement, and
Modernization Act of 2003 (MMA). Specifically, the MMA under Sec.
1860D-4 (Information to Facilitate Enrollment) requires CMS to conduct
consumer satisfaction surveys regarding Medicare prescription drug
plans and Medicare Advantage plans and report this information to
Medicare beneficiaries prior to the Medicare annual enrollment period.
The Medicare CAHPS survey meets the requirement of collecting and
publicly reporting consumer satisfaction information. The Balanced
Budget Act of 1997 also requires the collection of information about
fee-for-service plans. The CAHPS survey measures are incorporated into
the Part C and D Star Ratings that are published on www.medicare.gov
each fall to help consumers choose a Medicare plan. A subset of the
CAHPS measures is also included in the Medicare & You Handbook. CAHPS
information from MA contracts also feeds into the calculation of MA
Quality Bonus Payment Ratings that are required by statute and
regulation.
The primary purpose of the Medicare CAHPS surveys is to provide
information to Medicare beneficiaries to help them make more informed
choices among health and prescription drug plans available to them.
Survey results are reported by CMS in the Medicare & You Handbook
published each fall and on the Medicare Plan Finder website.
Beneficiaries can compare CAHPS scores for each health and drug plan as
well as compare MA and FFS scores when making enrollment decisions. The
Medicare CAHPS also provides data to help CMS and others monitor the
quality and performance of Medicare health and prescription drug plans
and identify areas to improve the quality of care and services provided
to enrollees of these plans. CAHPS data are included in the Medicare
Part C & D Star Ratings and used to calculate MA Quality Bonus
Payments. Form Number: CMS-R-246 (OMB control number: 0938-0732);
Frequency: Yearly; Affected Public: Individuals and Households Number
of Respondents: 794,500; Total Annual Responses: 794,500; Total Annual
[[Page 53109]]
Hours: 192,265. (For policy questions regarding this collection contact
Lauren Fuentes at 410-786-2290 or [email protected]).
William N. Parham, III,
Director, Division of Information Collections and Regulatory Impacts,
Office of Strategic Operations and Regulatory Affairs.
[FR Doc. 2024-13891 Filed 6-24-24; 8:45 am]
BILLING CODE 4120-01-P
